Avalo Therapeutics Files 8-K on Officer/Director Changes
Ticker: AVTX · Form: 8-K · Filed: Jan 2, 2025 · CIK: 1534120
| Field | Detail |
|---|---|
| Company | Avalo Therapeutics, INC. (AVTX) |
| Form Type | 8-K |
| Filed Date | Jan 2, 2025 |
| Risk Level | medium |
| Pages | 5 |
| Reading Time | 6 min |
| Key Dollar Amounts | $0.001, $450,000, $188,000 |
| Sentiment | neutral |
Sentiment: neutral
Topics: leadership-change, corporate-governance, filing
Related Tickers: AVTX
TL;DR
Avalo Therapeutics 8-K: Leadership shakeup, director elections, and new officer appointments on Jan 1, 2025.
AI Summary
On January 1, 2025, Avalo Therapeutics, Inc. (formerly Cerecor Inc.) filed an 8-K report. The filing indicates changes related to the departure of directors or certain officers, the election of directors, and the appointment of certain officers. It also covers compensatory arrangements for certain officers and other events, along with financial statements and exhibits.
Why It Matters
This filing signals potential shifts in the company's leadership and governance structure, which could impact strategic direction and operational execution.
Risk Assessment
Risk Level: medium — Changes in directors and officers can indicate internal restructuring or strategic shifts that may carry inherent business risks.
Key Players & Entities
- Avalo Therapeutics, Inc. (company) — Registrant
- Cerecor Inc. (company) — Former company name
- January 1, 2025 (date) — Date of earliest event reported
FAQ
What specific changes were made regarding directors and officers?
The filing indicates the departure of directors or certain officers, the election of directors, and the appointment of certain officers, as well as compensatory arrangements for certain officers.
What is the former name of Avalo Therapeutics, Inc.?
The former name of Avalo Therapeutics, Inc. was Cerecor Inc.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing was on January 1, 2025.
What is the principal executive office address for Avalo Therapeutics, Inc.?
The principal executive office address is 540 Gaither Road, Suite 400, Rockville, Maryland 20850.
What is the SIC code for Avalo Therapeutics, Inc.?
The Standard Industrial Classification (SIC) code for Avalo Therapeutics, Inc. is 2834, which corresponds to Pharmaceutical Preparations.
Filing Stats: 1,424 words · 6 min read · ~5 pages · Grade level 11.9 · Accepted 2025-01-02 07:04:39
Key Financial Figures
- $0.001 — ange on which registered Common Stock, $0.001 Par Value AVTX Nasdaq Capital Market
- $450,000 — ide Ms. Riley with (i) a base salary of $450,000 and (ii) a discretionary annual bonus w
- $188,000 — gregate total payments of approximately $188,000 for consulting services it provided to
Filing Documents
- avtx-20250101.htm (8-K) — 37KB
- ex-101employmentagreementx.htm (EX-10.1) — 94KB
- ex-991csoappointment.htm (EX-99.1) — 19KB
- avalologoa.jpg (GRAPHIC) — 8KB
- 0001628280-25-000005.txt ( ) — 307KB
- avtx-20250101.xsd (EX-101.SCH) — 2KB
- avtx-20250101_lab.xml (EX-101.LAB) — 21KB
- avtx-20250101_pre.xml (EX-101.PRE) — 12KB
- avtx-20250101_htm.xml (XML) — 3KB
01 Other Events
Item 8.01 Other Events. On January 2, 2025, the Company issued a press release announcing the appointment of Jennifer Riley as Chief Strategy Officer, effective January 1, 2025. A copy of the press release is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits: Exhibit No. Description 10.1 Employment Agreement, dated November 21, 2024, by and between Avalo Therapeutics, Inc. and Jennifer Riley . 99.1 Press Release dated J an uary 2 , 202 5 . 104 The cover pages of this Current Report on Form 8-K, formatted in Inline XBRL. 2 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. AVALO THERAPEUTICS, INC. Date: January 2, 2025 By: /s/ Christopher Sullivan Christopher Sullivan Chief Financial Officer 3